Hims & Hers to partner with Novo Nordisk and stop selling compounded GLP-1s

Telehealth company Hims & Hers on Monday announced a “strategic shift” in its business model, partnering with pharmaceutical company Novo Nordisk to sell its blockbuster GLP-1 medication and stop selling the “copycat” compounded versions it has long advertised.

In a press release, Hims & Hers said it will “no longer advertise compounded GLP-1 offerings on its platform or in its marketing, and existing patients will have the opportunity to transition to FDA-approved medicines when determined clinically appropriate by their providers.”

“We see tremendous growth opportunities in the US with the expanding assortment of branded GLP-1 medications,” said Andrew Dudum, co-founder and CEO of Hims & Hers.

“I’m excited to have a great partner in Novo Nordisk as we work to create a new model that works for everyday people. This collaboration reflects what’s possible globally when drugmakers, biotech companies, and diagnostic leaders partner with consumer platforms to support scaled distribution of their latest medical innovations.”

Hims & Hers will now offer Food and Drug Administration-approved semaglutide products, which include Novo Nordisk’s Ozempic and Wegovy, on a “limited scale.” This represents a drastic change for the online company, which has attributed the sale of compounded GLP-1s as a significant driver of its growth. The company even purchased a compounding pharmacy in 2024.

“This agreement with Hims & Hers is a meaningful win for patients in the United States. By expanding access through leading telehealth providers and digital care platforms, we are helping to connect more people with our FDA-approved medicines, which have been evaluated for safety and efficacy,” Novo Nordisk President and CEO Mike Doustdar said in a statement.

The collaboration between the two companies will offer both the injectable versions of semaglutide and the recently approved oral version of Wegovy.

This is not the first time the two companies have attempted to cooperate. When semaglutide came out of shortage, Novo partnered with several telehealth platforms to offer its GLP-1 products. The company ended its partnership with Hims & Hers soon after because the telehealth platform continued to offer compounded versions of Ozempic and Wegovy.

Just last month, Novo Nordisk filed a lawsuit against Hims & Hers for selling what it alleged to be “unapproved knock-off versions of Wegovy® and Ozempic®.”

On Monday, attorneys for Novo Nordisk submitted a notice of voluntary dismissal regarding the lawsuit.

This shift in its business model also comes as federal regulators have started to crack down on the sale of compounded GLP-1s. The Department of Health and Human Services had referred Hims & Hers to the Justice Department for possible criminal violations, and last week, the Food and Drug Administration sent out warning letters to 30 telehealth companies for the “illegal” marketing of compounded drugs.

Copyright 2026 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

More Health Care News

2 states approved permanent standard time. Others are hoping to do the same

Trump job approval sinks in new poll

GOP lawmaker makes formal switch to independent

Noem’s ouster could pave way to reopen shuttered Homeland Security Department

As DOJ lawyers face complaints, agency seeks tighter grasp on state bar ethics ...

The war on fraud is really a war on the poor

CBS justice correspondent leaving network: ‘I look forward to some ...

Watch live: Trump holds news conference amid Iran conflict, surging oil prices

Trump rejects UK’s offer to send aircraft carriers to Middle East: ‘We will ...

Live updates: Trump addresses House GOP in Miami; Graham presses Saudis to join ...

Republican NTSB member says he was fired; White House defends action

Senate Democrat says Congress should fund 4 agencies under DHS, continue ...

Trio of Habba successors are unlawfully leading NJ US attorney’s ...

Putin offers Mojtaba Khamenei ‘unwavering support’

Trump says he won’t sign any bills into law until SAVE America Act passes

Trump: Oil tanker crews must ‘show some guts,’ sail through Straight of ...

Newsom calls on DHS to direct Noem ad campaign funding to Los Angeles fire ...

Trump administration issues grand jury subpoena for Arizona voting records: GOP ...

© The Hill